Lupin Limited (LUPIN.NS)

NSE - NSE Delayed Price. Currency in INR
1,500.10-5.75 (-0.38%)
At close: 5:59 AM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close1,505.85
Bid0.00 x
Ask1,500.10 x
Day's Range1,492.25 - 1,518.45
52wk Range1,280.00 - 2,096.85
1y Target EstN/A
Market Cap676.46B
P/E Ratio (ttm)26.29
Avg Vol (3m)1,017,657
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Reuters8 days ago

    Bayer's medical skin creams draw suitors Lupin, BC Partners -sources

    Bayer has short-listed India's Lupin and investor BC Partners as prospective buyers of medical skin cream assets in a potential 1 billion euro ($1.1 billion) deal, several people familiar with the sale told Reuters. Germany's Bayer has for more than two years sought to narrow the focus of its healthcare division and its planned $66 billion Monsanto takeover has added urgency to that drive. Bayer has, however, said a debt package and cash call would suffice to finance the Monsanto purchase, its largest ever transaction.

  • Bloomberg22 days ago

    Lupin Expects U.S. Approvals From Goa Factory in Two Months

    Lupin Ltd., India’s second-biggest drugmaker by market value, expects U.S. approvals for new products from its facility in the coastal state of Goa to begin again in the next two months as it addresses ...

  • Reuters4 months ago

    India's Sun Pharma bets on new products to boost U.S. skincare products growth

    India's largest drugmaker Sun Pharmaceutical Industries is banking on the launch of newer and more complex products to offset rising competition in its lucrative U.S. dermatology business, its U.S. chief said. The world's fifth-largest maker of generic drugs was the first among its Indian peers to enter the roughly $5 billion U.S. dermatology space by acquiring a controlling stake in Israel's Taro Pharmaceutical Industries Ltd in 2010.